First Page | Meta Content | |
---|---|---|
![]() | Document Date: 2013-05-15 16:44:38Open Document File Size: 281,47 KBShare Result on FacebookCityWashington / DC / La Jolla / /CompanyBerkeley Research Group / /ContinentAmerica / /CountryUnited States / /CurrencyUSD / /FacilityProgram May Distort Pharmacy / Pharmacy Markets / Hospital Eligibility / Pharmacy Affairs / Hospital Markets / /IndustryTerminsurance coverage / law exempts / prescription drug insurance / transparent accounting / contract pharmacy site / 340B law / health care services / biopharmaceutical manufacturers / pharmaceutical manufacturers / preventive services / /MedicalConditionsexually transmitted disease / cancer / hemophilia / tuberculosis / /OrganizationCongress / Community Oncology Alliance / Congress’ Medicare Payment Advisory Commission / U.S. House of Representatives / U.S. Census Bureau / 340B hospital / US Federal Reserve / office of Pharmacy Affairs / National Patient Advocate Foundation / Government Accountability Office / Biotechnology Industry Organization / Department of Veterans Affairs / Department of Health and Human Services / Congressional Budget Office / Health Resources and Services Administration / National Community Pharmacists Association / Pharmaceutical Care Management Association / Medicare / /PersonNonprofit Hospitals / Mary Wakefield / /PositionExecutive / Administrator / General / Secretary / contents Executive / /ProvinceOrStateCalifornia / /PublishedMediumPublic Law / /TechnologyBiotechnology / pdf / /URLwww.cbo.gov/sites/default/files/cbofiles/attachments/43472-07-24-2012-CoverageEstimates.pdf / http /SocialTag |